Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo

Inhibition of proteasome-associated deubiquitinases (DUBs) is emerging as a novel strategy for cancer therapy. It was recently reported that auranofin (Aur), a gold (I)-containing compound used clinically to treat rheumatoid arthritis, is a proteasome-associated DUB inhibitor. Disulfiram (DSF), an i...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Hongbiao, Liao, Yuning, Liu, Ningning, Hua, Xianliang, Cai, Jianyu, Yang, Changshan, Long, Huidan, Zhao, Chong, Chen, Xin, Lan, Xiaoying, Zang, Dan, Wu, Jinjie, Li, Xiaofen, Shi, Xianping, Wang, Xuejun, Liu, Jinbao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823072/
https://www.ncbi.nlm.nih.gov/pubmed/26625200
http://dx.doi.org/10.18632/oncotarget.6425

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823072/
https://www.ncbi.nlm.nih.gov/pubmed/26625200
http://dx.doi.org/10.18632/oncotarget.6425

Ejemplares similares